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Statement of Translational Relevance 
Despite recent publication of numerous putative biomarkers of prostate 
cancer we are still completely dependent clinically on serum PSA. There is 
still an urgent need for new markers and particularly those identifying 
significant cancers. This study evaluates a transcription factor secreted by 
prostate cancer as a simple ELISA test without the requirement for DRE.  The 
sensitivity, specificity and stability of EN2 at room temperature would make 
this test attractive for diagnosis of prostate cancer and also potentially as a 
simple screening tool in the community. 
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Abstract 
 
Purpose: Prostate cancer (PC) is the second most common cause of cancer 
related death in men. A number of key limitations with prostate specific 
antigen (PSA), currently the standard detection test, has justified evaluation of 
new biomarkers. We have assessed the diagnostic potential of EN2 protein, a 
homeodomain-containing transcription factor expressed in PC cell lines and 
secreted into the urine by PC in men.  
 
Experimental Design: EN2 expression in PC cell lines and prostate cancer 
tissue was determined by semi-quantative RT-PCR and 
immunohistochemistry. First pass urine (without prior digital rectal 
examination (DRE)) was collected from men presenting with urinary 
symptoms (referred to exclude/confirm the presence of prostate cancer) and 
from controls. EN2 protein was measured by ELISA in urine from men with 
PC (n=82) and controls (n=102). 
 
Results: EN2 was expressed and secreted by PC cell lines and PC tissue but 
not by normal prostate tissue or stroma. The presence of EN2 in urine was 
highly predictive of PC, with a sensitivity of 66% and a specificity of 88.2%, 
without requirement for DRE. There was no correlation with PSA levels. 
These results were confirmed independently by a second academic centre. 
 
 4
Conclusions: Urinary EN2 is a highly specific and sensitive candidate 
biomarker of prostate cancer. A larger multicentre study to further evaluate 
the diagnostic potential of EN2 is justified.  
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Introduction 
 
Prostate cancer (PC) is the second most common cause of cancer related 
death in men, with approximately 913,000 new cases world wide in 2008 (1). 
Localised, organ-confined PC can be cured in a large proportion of patients by 
surgery or radiotherapy. Advanced and metastatic PC continues to be 
associated with a poor prognosis (2). Serum prostate specific antigen (PSA) 
has been used as a cancer marker for initial diagnosis, monitoring of 
response to treatment, prediction of PC risk and of treatment outcome. As a 
prostate-specific and not prostate cancer-specific marker, it lacks both 
sensitivity and specificity to accurately detect the presence of PC, requires 
adjustment for age and prostate volume, is frequently raised in non-cancer 
conditions such as benign hypertrophy and prostatitis and so far has been 
controversial as a screening tool (3-5). A conventional cut off level of 4ng/ml 
has predictive value for detection of the prostate cancer (6,7)  but only 15% of 
cancers were detected at prostate biopsy in the Prostate Cancer Prevention 
Trial (PCPT) (8). Higher detection rates of up to 44% have been reported at 
this PSA level in other studies, but these, unlike PCPT, did not evaluate 
healthy asymptomatic men (8-10). Studies of men at different ages also 
suggests differential incidence of prostate cancer. For the third through eighth 
decades of life, the incidence of prostate cancer in the cohort of 1051 subjects 
studied by Sakr et al was 7%, 23%, 39%, 44%, and 65%, respectively (11). 
Lowering PSA cut off levels results in higher sensitivity at the expense of 
much lower specificity and true negative rates of 70-80% (8, 12, 13). No 
refinement of PSA (e.g. free: total PSA ratio) or other biomarkers have 
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reduced this true negative rate (13).There is therefore an urgent need for new 
markers to overcome at least some of the limitations of serum PSA. 
 
Biomarkers signifying the presence of any cancer may be defined on the 
basis of gene products uniquely expressed or overexpressed in tissue, serum 
or urine, in cancer compared to non-cancer. A number of genes are involved 
in early embryonic development and are subsequently re-expressed in 
cancer, for example the HOX genes, a family of homeodomain-containing 
transcription factors that determine the early identity of cells and tissues (14). 
We and others have shown that HOX gene dysregulation occurs in most 
common cancers, with evidence that targeting HOX/PBX binding has 
therapeutic value (15-19). We have studied Engrailed-2 (En2), another 
member of this group which show a very high degree of functional 
conservation during development (20). En2 is a transcriptional repressor, but 
is also has a role in translational regulation (20). In addition to its 
developmental role, En2 has recently been shown to be a potential oncogene 
in breast cancer, as forcing its expression in the non-malignant mammary 
cells induces a malignant phenotype including increased cell proliferation and 
a loss of contact dependence (21).  
 
In this study we show that En2 is expressed in, and secreted by, prostate 
cancer but not normal prostatic tissue. The presence of EN2 protein in urine 
has been evaluated as a diagnostic biomarker for PC. 
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 Materials and Methods 
 
Patient and controls  
This study was approved by the local research ethics committee (reference 
09/H1109/84), and took place between June 2007 to June 2010. In total 194 
urine samples were collected by the Surrey site. Men with lower urinary tract 
symptoms, individuals concerned they may have an asymptomatic PC (e.g. a 
positive family history) and men with an abnormal PSA test reading conducted 
by their family physician were referred into our specialist Uro-Oncology clinic. 
The purpose of the referral was to exclude or confirm the presence of prostate 
cancer. Men with known PC on treatment, with any other known concurrent or 
previous cancers within 10 years or urinary tract infection (as determined by 
the presence of leukocytes using a dipstick test) were excluded. Urine 
samples from patients and controls were collected prospectively; samples 
were blinded to laboratory staff at the time of EN2 measurement.  
Two control groups of men >40 years were also assessed: 
(a) ‘low PSA group A’; men presenting to haematuria clinics where no 
urothelial malignancy was found (single episode of haematuria: radiology, 
cystoscopy and cytology negative) but in whom DRE and PSA (routinely 
performed in this clinic) were normal, PSA below 2·5 ng/ml. 
 (b) ‘low PSA group B’; men over 40 years with no symptoms or family history 
of PC and who had undergone routine health screening by family physicians 
(conducted once or twice yearly: physical examination, diabetes screening of 
serum and urine, serum cholesterol and serum PSA levels even in the 
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absence of lower urinary tract symptoms and family history of prostate 
cancer) and had a documented PSA below 2·5 ng/ml. 
The majority of samples were donated the day after consultation. 5-10mls of 
first pass urine samples were donated pre-biopsy, prior to any hormone 
therapy and not immediately after DRE (range 4-24 hours post DRE). For the 
non-cancer control groups no DRE was performed prior to urine donation.  
Urine was stored in 1·5 ml aliquots at -80°C. Blood for PSA analysis was 
always drawn before urine collection. Histological examination of prostate 
biopsies was performed by a specialist uro-pathologist. The 2003 UICC TNM 
classification was applied. Gleason scores, clinical stage and PSA were 
available in all cancer cases.  
 
EN2 protein detection – western blotting 
1·5ml of urine were centrifuged at 10,000g for five minutes to remove cells 
and cellular debris. 20μl of the supernatant were then mixed directly with gel 
running buffer (Invitrogen, Paisley, UK).   Proteins were resolved by 10% 
SDS–polyacrylamide gel electrophoresis and transferred to a polyvinylidene 
fluoride membrane (Invitrogen, Paisley, UK).  Anti-EN2 antibody (ab45867; 
Abcam, Cambridge, Cambridgeshire, UK) was used at a concentration of 
0·5µg/ml, and a goat-anti human IgG peroxidise-labelled antibody was used 
together with the ECL chemiluminescent system for detection. 
 
EN2 protein detection – Enzyme-linked Immunosorbent Assay (ELISA) 
Two monoclonal mouse anti-EN2 antibodies were raised using the 
synthetically produced C-terminal 100 amino acids (Biosynthesis Inc, 
Lewisville, Texas,  USA) of EN2 as an antigen (Antibody Production Services 
 9
Ltd, Haywards Heath, Sussex, UK). One of these, APS1, was conjugated to 
alkaline phosphatase using the Lightning Link alkaline phosphatase 
conjugation kit (Innova Biosciences, Cambridge, Cambridgeshire, UK), whilst 
the other, APS2, was conjugated to biotin using the Lightning Link Biotin 
Conjugation kit (Innova Biosciences, Cambridge, Cambridgeshire, UK). 
APS2-biotin was captured onto a 96-well streptavidin-coated plate (Nunc 
436014, Rochester, New York, USA) at a concentration of 4μg /ml. After 
washing, 100μl of urine or a dilution of the EN2 fragment in buffer was 
incubated in each well for 1 hour at room temperature. The plate was then 
washed 8 times in buffer (PBS with 0·1% Tween-20) and the secondary 
detection antibody – APS1-Alkaline phosphatase was added to each well at a 
concentration of 4μg/ml (1 hour at room temperature). After a final wash step 
a colormetric agent – pNPP (Sigma, St Louis, MO, USA) was added and the 
absorption of light at 405nm was measured after one hour. The dilution series 
was used to generate a standard curve by which the concentration of EN2 in 
each sample was measured (supplemental figure 2). 
 
cDNA Synthesis  
RNA from prostate tumours and normal adjacent tissue was obtained from 
urology clinic patients. Prostate biopsy tissue was taken contiguous to a 
routine sextant biopsy (from which histology was later confirmed), placed in 
OCT (optimal cutting compound), snap frozen and stored in liquid nitrogen. 
RNA was reverse transcribed as described previously (16). RNA was first 
denatured by heating at 65oC for five minutes. 1-5μg of RNA was incubated in 
a volume of 50μl at 37oC for one hour with final concentrations of 10mM DTT, 
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1mM dNTP mix, as well as 100ng/μl polyT primers, 200 units of reverse 
transcriptase (Invitrogen, Carlsbad, CA, USA) and 40 units of RNaseOUT 
(Invitrogen, Carlsbad, CA, USA).  The cDNA synthesis reaction was 
terminated by placing tubes at 80oC for five minutes. 
 
Semi-quantitative RT-PCR 
Semi-quantitative RT-PCR was performed using the Stratagene MX4000 Real 
Time PCR machine, measuring PCR product accumulation during the 
exponential phase of the reaction by SYBR green fluorescence. Reaction 
conditions were 1 cycle of 94oC for 10 minutes, followed by 40 cycles of 30 
seconds at 94oC, 1 minute at 60oC and 30 seconds at 72oC. The forward and 
reverse primers for En2 were 5’ GAACCCGAACAAAGAGGACA 3’ and 5’ 
CGCTTGTTCTGGAACCAAAT 3’, and for Beta actin they were 5’ 
ATGTACCCTGGCATTGCCGAC 3’ and 5’ GACTCGTCATACTCCTGCTTG 
3’. 
 
Immunohistochemistry 
Expression of EN2 in PC and normal prostate was investigated using 3μm 
thick formalin fixed, paraffin embedded tissue array (PR2085a, US Biomax, 
Rockville, MD, USA) and patient prostate biopsies. Immunohistochemical 
analysis was performed using a polyclonal rabbit anti-EN2 antibody (Abcam, 
Cambridge, Cambridgeshire, UK #28731) diluted 1:100 and the ABC 
detection method with peroxidase block (DakoCytomation). Brain sections 
were used as a positive control. Antigen retrieval was performed using pH9.0 
Tris/EDTA buffer (DakoCytomation) and heating in a microwave for 23 
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minutes. The tissue arrays described in this study were stained using the 
same method and were obtained from Biomax US (PR2085a). 
 
Cell culture 
PC3 (22), DU145 (23), and LNCaP (24), prostate cancer cell lines, together 
with WPMY-1, a non-malignant fibroblast line derived from prostate stroma 
(25), were obtained from the ATCC (through LGC Standards UK), and 
maintained according to ATCC protocols supplied for each cell line. The 
conditioned media used for EN2 detection was taken from cells grown to 90% 
confluence without a media change after seeding 10% confluence. 
 
Statistical analysis 
The Graphpad prism package was used in statistical calculations. In order to 
test the significance of differences between mean EN2 concentrations in 
different patient groups we used an unpaired t-test with Welch’s correction. 
Receiver operator characteristics (ROC) curves were generated for the EN2 
and PSA values. The area under the curve was tested for significance using 
an unpaired t-test against the hypothesis that the real area under the curve 
was 0·5 (i.e. no diagnostic value). 
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Results 
 
The complex regulatory functions and oncogenic potential (20) of En2 led us 
firstly to study the expression of En2 in PC cell lines. The differential 
expression of En2 by malignant versus non-cancer cells was studied by 
measuring the number of En2 transcripts in the human PC cell lines PC3, 
DU145, and LNCaP together with a non-malignant cell line derived from 
normal prostate fibroblasts, WPMY-1 (Fig 1a). Of these lines, PC3, DU145 
and LNCaP all expressed En2. In addition, RNA was extracted from prostate 
biopsy cores and En2 expression quantified by quantitative PCR. Of 12 cores 
that were histologically positive for cancer 10 expressed En2, whilst none of 
the 8 cores negative for cancer showed En2 expression (Fig 1b). As EN2 
protein can be secreted physiologically from some types of cell (20, 26) we 
looked for the protein in the conditioned medium surrounding PC3, DU145, 
LNCaP and WPMY-1 cells by Enzyme-linked Immunosorbent Assay (ELISA).  
PC3, LNCaP and DU145 cell lines release EN2 protein into the surrounding 
medium, but not WPMY-1 (Fig 1c), and immunofluorescent imaging of EN2 in 
PC3 cells revealed a high concentration of this protein close to the membrane 
consistent with its secretory potential (Fig 1d). 
 
These findings were supported by immunohistochemical study of PC and 
normal prostatic tissue using an anti-EN2 antibody stain in a large 
representative 195 core tissue array and in patient biopsies. In the tissue 
array EN2 was highly expressed in prostate cancer (92%, n=184 prostate 
cancer cores), but not in normal tissue adjacent to the tumour (0%, n=11), or 
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in normal prostate cores (0%, n=9). We found no evidence of EN2 staining in 
normal prostate tissue, benign hypertrophy nor in men with HGPIN (high 
grade prostatic intra-epithelial neoplasia) in any tissue array section or biopsy 
from our patients. Analysis of larger tumour sections taken by biopsy revealed 
EN2 expression is most intense in the duct like structures of tumours (Fig 2a-
c), and that EN2 protein is present in the cytoplasm, and in some cases in the 
basal membrane, but not in the nucleus (Fig 2c). Furthermore, blebs 
containing EN2 protein are apparent in prostatic acini and ducts (Fig 2b, c).  
This widespread distribution contrasts markedly with normal adult purkinje 
neurons where EN2 protein, as expected, is confined to the nucleus (27) 
(supplemental Fig 1). We also compared the staining of EN2 to that of a 
known prostate cancer specific antigen, alpha-methylacyl-coenzyme A 
racemase (AMACR) (28); merged images of each staining pattern show an 
almost complete overlay (Fig 2d-f).  
 
Given the secretory properties of EN2 in embryonic development (29) and the 
observation of EN2-positive blebs within the lumen of malignant prostatic 
ducts, we looked for EN2 protein in the urine of men with biopsy-confirmed 
but untreated PC and controls. EN2 protein in untreated, unconcentrated 
urine from PC patients could be detected by western blotting with a band 
corresponding to full length EN2 protein (33kDa; Fig 3), but not after 
prostatectomy in the same patients and not in non-cancer individuals.  
 
The ELISA assay for EN2 (supplemental Fig 2) was used to screen 
representative populations of patients with prostate cancer and relevant 
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controls. The stability of EN2 protein in urine was shown to be at least four 
days at room temperature (supplemental Fig 3), allowing postal collection of 
some samples.  The demographics of patients and control groups are shown 
in table 1. The mean age of men in the study was similar (range 57-67 years). 
Median PSA (6·3-7·6 ng/ml) was similar in men suspected of PC versus the 
two low PSA control groups (0·9-1·1 ng/ml), as expected. Using a cut off of 
42·5μg/L, EN2 protein was detected in 54 of the 82 (66%) men with PC 
confirmed by biopsy (‘Biopsy (+)’). Notably, in 9 men in this EN2 positive 
group the PSA was < 2.5 ng/ml. In men with high PSA and no cancer on 
biopsy (‘Biopsy (-)’), EN2 was detected in 6 of 58 (10·3%). In our control 
groups EN2 detection was also infrequent: in ‘low PSA group A’ EN2 was 
detected in 2 of 17 (11·7%); in low PSA group B EN2 was detected in 4 of 27 
(14·8%). An exceptionally high level of EN2 was found in the urine of one 
individual in control ‘low PSA group B’ who had a PSA of 1.2ng/ml. 
 
An ROC analysis for this data (Biopsy (+) v Biopsy (-)) revealed that the area 
under the curve was 0.8021 (p<0·001), indicating a high diagnostic potential 
for EN2 (Fig 4b). The mean concentration of EN2 protein was 10·4 fold higher 
in PC patients compared to that in all the men that were not known to have 
cancer (Fig 4a). We found no significant correlation between EN2 expression 
and combined Gleason score, although the majority of patients in our cohort 
had disease with a combined Gleason score of 6 or 7 (Fig 5a). There was 
also no significant correlation between serum PSA level and presence or 
absence of urinary EN2 (Fig 5b). EN2 was also found in the urine of 3 of 10 
men (30%) with high grade prostatic intraepithelial neoplasia (HGPIN; Table 
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1; Fig 4a); two of these 3 men were found to have PC within 6 months upon 
re-biopsy. 
In order to validate our findings with respect to urinary EN2 secretion, a 
similar study was completed independently at Cambridge University following 
the same collection protocol. EN2 detection by ELISA followed exactly the 
same protocol as for the Surrey University study. The results are summarised 
in Table 1 and are similar to those obtained for the Surrey patients. Of 13 
control patients two were found to have EN2 in their urine (15%), whilst 47 of 
81 patients with prostate cancer were positive for EN2 (58%). 
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Discussion 
 
In this study we have shown that the transcription factor En2 is expressed by 
PC-derived cell lines and in primary prostate tumours, but not in normal 
prostate tissue. Our data indicates that EN2 protein is also secreted by both 
cell lines and primary tumours, and is found in the majority of PC patients in 
first pass urine collected without preceding DRE, but not in non-cancer 
controls. We found that EN2 is associated with a sensitivity of 66% and 
specificity of almost 90% using the 42·5 ng/ml cut off. The maximum 
specificity that can be achieved using this assay is 100%, using a cut off at 
1927 ng/ml, but the resulting sensitivity is only 2·5%. The maximum sensitivity 
(73%) is achieved using a cut off at 1·5 ng/ml and the resulting specificity is 
80%. The cut off value of 42·5 ng/ml was selected to give both high sensitivity 
and specificity. 
 
PSA is a valuable tool for the early detection and monitoring of PC, but PSA 
values vary with prostate volume, age and raised levels are seen in non-
cancer disorders such as prostatitis. The specificity and sensitivity of PSA has 
been difficult to fully determine as men with low PSA levels rarely undergo 
biopsy. The Prostate Cancer Prevention Trial (PCPT) biopsied 5112  men in 
the placebo arm  irrelevant of PSA level. A PSA >4ng/ml had a sensitivity of 
24% and specificity of 93% (30). The same study confirmed clinical 
experience that some PC are associated with very low levels of PSA 
production. PC was present in 6·6% of men where PSA <0·5ng/ml and 27% 
men had PSA of 3·1-4 ng/ml (8). Ultimately the choice of PSA ‘cut off’ 
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balancing sensitivity against specificity results in false positive tests and large 
numbers of unnecessary biopsies (31, 32). A recent study has indicated that 
PC mortality may be reduced almost by half over 14 years by early detection 
by PSA in a screening program. Although this was achieved at the expense of 
‘over diagnosis’ the potential value of biomarkers in early disease was 
demonstrated (5). There have been no new serum based prostate cancer 
detection tests sufficiently specific or sensitive to reach the clinic in the last 
decade. Recently published urine-based tests share the limitations of PSA to 
varying extents and mostly require urine collection post-DRE. Most notable 
amongst these is PCA3, a non-coding RNA present in urine (33) and Annexin 
A3 (34). PCA3 has a higher specificity than PSA (76% to 89%) and the 
detection rate of PC is reported to be 34%, but it still gives significant numbers 
of false positive results (33). Furthermore it requires urine post-DRE and is 
expensive and complex to use. It is used to help decide whether to proceed to 
repeat prostate biopsy in cases where the PSA is persistently high.  Annexin 
A3 is a protein present at higher concentrations in patients that have PC, and 
has a sensitivity and specificity of 31.2% and 90%, respectively (34). It only 
has utility in conjunction with urinary PSA measurements, which themselves 
are subject to all the potential flaws of serum PSA discussed earlier. Other 
recently described urinary prostate cancer biomarker approaches that have 
been based on matrix modelling of multiple markers (35) are complex, not 
immediately applicable to routine clinical practice and may be more 
appropriate for stratifying patients in clinical trials. In contrast, EN2 can be 
detected in 100μl of unprocessed urine, collected without the requirement for 
DRE and employs a simple enzymatic detection method. DRE expels cells 
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into urine and is the basis of tests such as PCA3 where mRNA from these 
expelled cells is extracted. EN2 is secreted by the prostate cancer cells, the 
cellular component of the collected urine is discarded and only the 
supernatant evaluated after spinning down. We have seen negligible changes 
in EN2 concentrations pre-DRE and post-DRE urine to date (n=12). This is 
being further evaluated in our current follow up study in larger numbers of 
individuals. The clinical potential of EN2 is further supported by our findings of 
its stability in urine at room temperature for at least 4 days without 
preservative allowing routine transport of samples to diagnostic labs.   
 
The high predictive value of urinary EN2 raises the possibility that it could be 
used alongside PSA in the primary diagnosis of PC in patients presenting with 
lower urinary tract symptoms or a family history of PC, and reduce 
unnecessary prostate biopsies. Further potential utility of EN2 as a prostate 
cancer biomarker was demonstrated by its presence in the urine of men with 
low PSA (<2.5 μg/L) but histologically confirmed prostate cancer on biopsy 
(n=9). Non-PSA secreting PC represent a small proportion of all cases but are 
problematic (36). This study found high levels of EN2 in the urine of one 
individual from our control group 1 (he was asymptomatic:no urinary 
symptoms, weight loss or pain suspicious of metastatic involvement,  and had 
a PSA of 1·2 during a general health screening by his family physician). It is of 
course possible that he and individuals designated ‘false positive’ in this study 
may be harbouring non-PSA secreting PC or have PC present in transitional 
zone or the anterior horn of the peripheral zone. This patient was discussed 
with the ethics committee and referred to a urologist for further assessment.  
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 The  ELISA based assay we have developed will potentially allow a number of 
different detection platforms including a lateral flow application with a ‘dip 
stick’ test  which could be performed quickly and cheaply in primary care or as 
a component of a large scale screening program (if justified by further 
studies). EN2 may therefore be positioned as an adjunct to PSA for diagnosis 
in symptomatic or ‘at risk’ individuals (e.g. positive family history,  HGPIN), in 
men with ‘bordeline’ PSA levels or in general population screening in view of 
its simplicity and no requirement for DRE.  The greatest uptake would most 
likely be by family physicians for these reasons. The expression of EN2 in the 
tissue and urine of individuals with other urothelial cancers (renal, bladder and 
ureteric) is currently being determined to address its ultimate specificity for 
prostate cancer. In addition, a larger multicentre study is planned to determine 
whether EN2 could be used as a monitoring tool (PSA was originally 
approved for this purpose), the effect of surgery, hormonal and radiotherapy 
on EN2 secretion into urine, and also whether levels of urinary EN2 correlate 
with tumour stage and Gleason grade. However, as with every PC biomarker 
in development, the ultimate question will be centred around the utility of EN2 
(alone or in combination with other markers) in identifying ‘significant’ cancers 
that require early intervention. 
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FIGURE LEGENDS 
 
 
 
Figure 1. En2 expression in prostate cancer. (a) RT-QPCR analysis of En2 
expression in the PC-derived cell lines PC3, LNCaP, and DU145, and the non 
malignant, stromal derived fibroblast line WPMY-1. Expression is shown 
relative to the Beta-actin gene (x10000).  (b) RT-QPCR analysis of En2 in 
biopsies that were found to be histologically positive (‘PC’) or negative (‘Non 
PC’) for prostate cancer. *** denotes p<0.001. Expression is shown relative to 
the GAPDH gene (x10000). (c) EN2 protein is present in the conditioned 
medium from prostate cancer cell lines. EN2 protein in the media surrounding 
PC3, DU145, LNCaP and WPMY-1 cells was quantified using Enzyme-linked 
Immunosorbent Assay (ELISA). (d) Immunofluorescent microscopy showing 
the distribution of EN2 protein in PC3 cells. Arrowheads indicate high 
concentrations of EN2 adjacent to the membrane. Left image – EN2 staining 
only (green). Right image – EN2 staining (green), merged with DAPI staining 
(showing the position of the nucleus, blue) and a light micrograph. Scale bar: 
5μm. 
 
Figure 2 (a) Core biopsy of a prostatic adenocarcinoma stained with anti-EN2 
antibody. EN2 positive staining (brown) is present in tumour cells. 
Magnification: x30. (b) Higher magnification of a tumour duct. EN2 is present 
in the cytoplasm of tumour cells, with strongest staining at the luminal border 
(1). EN2 positive blebs are visible attached to the luminal border (2) or free 
within the lumen (3). The nuclei are stained blue. Magnification: x100. (c) A 
malignant prostatic acinus showing strong EN2 staining in the cytoplasm and 
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within a secretory bleb (S), but not in the nuclei (N). Magnification: x120. (d-f) 
Section through a prostate tumour; tumour cells are stained using the prostate 
cancer specific antigen Alpha-methylacyl-coenzyme A racemase (AMACR) 
(d). The same section was also stained with fluorescently labelled anti-EN2 
(green) (e). The merged image reveals an almost identical pattern of staining 
(f). Magnification (d-f): x60. 
 
Figure 3. EN2 protein detection in urine by western blot. Urine was collected 
from individuals being examined for urinary symptoms consistent with 
prostate cancer, and controls. The presence of PC was confirmed by biopsy. 
The predicted MW of EN2 is 33 kDa and a band of this size was observed 
exclusively in the urine of some patients with prostate cancer. The 
representive blot shows a positive result for a patient with PC pre-
prostatectomy but not post-prostatectomy, nor in men with BPH, HGPIN and 
men under 30 where PC would not reasonably be expected to be present. 
 
Figure 4 (a) Quantitation of EN2 by ELISA. The concentration of EN2 was 
determined by ELISA for urine samples from each group. The mean value for 
[EN2] determined by ELISA is shown for each group and error bars represent 
the standard error of the mean. Patient group abbreviations are described in 
Table 1. An unpaired t-test with Welch’s correction was used to calculate the 
significance of the mean EN2 concentration for PC and non-cancer diagnosis 
groups (*** denotes that p<0.001). (b) An ROC analysis of urine EN2 
concentrations in men with biopsy proven prostate cancer (Biopsy (+)) v the 
men that were a biopsy did not find PC (Biopsy (-))  in the Surrey cohort. 
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 Figure 5 (a) A comparison of mean EN2 concentrations in urine from PC 
patients subdivided into those with a Gleason score of G6 to G10. The error 
bars represent the standard error of the mean. The difference in the mean 
value for each group is not statistically significant (p>0·05). (b) A vertical 
scatter plot representing the serum PSA concentrations of patients found to 
have PC. These are split into two groups, patients whose urine was positive 
for EN2 (EN2+), and negative for EN2 (EN2-). The horizontal bar represents 
the mean value for each group; the P value associated with these means is 
shown. ‘Combined’ – data for all patients in this group.  
 
Table 1 Summary of patient demographics and urine screening results using 
an ELISA to quantify EN2 protein. ‘Biopsy (+)’, patients found to have PC 
upon biopsy. ‘Biopsy (-)’, men with a raised PSA but found to be negative for 
prostate cancer upon biopsy. ‘Low PSA A’, men with a low PSA (<2·5ng/ml) 
selected from patients attending a haematuria clinic that were not found to 
have disease; ‘Low PSA B’, men with a low PSA (<2·5ng/ml) that were 
assessed as part of a community screening program.  ‘Surrey’ indicates 
Surrey patient cohort; ‘Cambridge’ indicates Cambridge patient cohort. The 
sample collection and EN2 assay were performed independently by these two 
centres. 
 
Supplementary figure 1 EN2 in purkinje cells. A section through a human 
cerebellum showing the cell bodies of a number of purkinje cells (the large 
cells). There are small foci of immunoreactivity (brown speckled staining) 
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within cell nuclei of purkinje cells and not other neuronal cells or supporting 
tissue. Magnficiation: x200. 
 
Supplementary figure 2 Enzyme-linked Immunosorbent Assay (ELISA) for 
EN2 protein in urine. (a) Standard curve for equating light absorbtion at 
405nm (‘OD’) to the concentration of EN2. (b) Intra assay variation. A single 
urine sample was measured 22 times in the same assay. A summary of the 
primary output (i.e. OD at 405nm) is shown.  
 
Supplementary figure 3 EN2 protein is stable for at least 4 days at room 
temerature. Urine samples that contained full length EN2 protein (as 
determined by western blotting) were stored at room tempertaure for two 
weeks and tested again for full length EN2 protein after 4, 7 and 13 days. ‘+’ 
indicates the presence of full length EN2 protein (i.e. a 33kDa band detected 
by western blotting) and ‘-‘ indicates its absence. 
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Table 1 
 
Surrey University 
 
Group n Mean age 
(range) 
Mean PSA 
(range) 
Median 
PSA 
%EN2 +ve
Biopsy (+) 82 67 (44-83) 15 (1.9-
175) 
7.3 66 
Biopsy (-) 58 66 (52-82) 9 (0-12) 7.6 10.3 
Low PSA 
A 
17 63 (42-84) 1.2 (0.4-
2.6) 
1.1 11.7 
Low PSA 
B 
27 57 (45-86) 1.1 (0.2-3) 0.9 14.8 
All non Ca 102 63 (42-86) 5.8 (0.2-
30) 
4.6 11.8 
HGPIN 10 63 (50-78) 8.27 (2.5-
16) 
7.7 30 
 
Cambridge University 
 
Group N Mean age 
(range) 
Mean PSA 
(range) 
Median 
PSA 
%EN2 +ve
Biopsy (+) 81 67 (40-85) 151.8 (1.9-
6510) 
7.3 58 
Biopsy (-) 13 60 (45-78) 6.4 (2.2-
11.8) 
6.3 15 
 
